[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561171":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":19,"responsibleParty":31,"collaborators":19,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":19,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":19,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":55,"overallStatus":59,"whyStopped":19,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":19},{"fullName":5,"class":6},"First Affiliated Hospital of Xinjiang Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"inclisiran Therapy group","EXPERIMENTAL","Patients with carotid plaques undergoing treatment with inclisiran",[13],"Drug: Inclisiran",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","Inclisiran",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Zhenyan Fu, PhD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},"Yuanhao Yao, MD","CONTACT","09914366872","+86","yyh991012@outlook.com",{"type":23,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Zhenyan Fu, PHD","Pricinple Inverstigator","100561171","phase-4-effect-of-small-interfering-rna-inclisiran-on-carotid-plaques-as-assessed-by-carotid-ultrasound-100561171",false,"NCT06586684","Effect of Small Interfering RNA Inclisiran on Carotid Plaques As Assessed by Carotid Ultrasound","The Effect of Small Interfering RNA Inclisiran on Carotid Plaques in Patients with Atherosclerosis: a Real-world Study Using Carotid Ultrasound.","Inclusion Criteria:\n\n* Patients with carotid plaques as indicated by ultrasound\n* Men and women aged 18-75 years;\n* LDL-C \\>3.4 mmol\u002FL without regular statin therapy or LDL-C \\>1.8 mmol\u002FL after 4 weeks of statin lipid-lowering therapy.\n\nExclusion Criteria:\n\n* \\- Known allergies or contraindications to PCSK9 inhibitors and\u002For statin therapy;\n* Prior use of PCSK9 inhibitors;\n* Prior history of hemorrhagic stroke;\n* Prior coronary artery bypass grafting or coronary intervention;\n* Inability to perform OCT imaging or unclear imaging;\n* Severe renal insufficiency (creatinine clearance \\< 30 mL\u002Fmin);\n* Severe hepatic dysfunction;\n* Baseline triglycerides \\> 5.6 mmol\u002FL;\n* Pregnant or lactating women;\n* Life expectancy not exceeding 1 year;\n* In the judgment of the investigator, unsuitable for this study for any reason.","ALL","18 Years","75 Years",{"count":45,"type":46},40,"ESTIMATED","INTERVENTIONAL",[49],"PHASE4","Current understanding suggests that the majority of cardiovascular events are driven by vulnerable plaques. Nonetheless, the impact of PCSK9 inhibitors on the stability of carotid plaques remains insufficiently elucidated, with a notable scarcity of relevant clinical studies. This investigation seeks to address this gap through a real-world study conducted among patients with arterial sclerosis in Asia. The primary aim is to evaluate the effects of small interfering RNA (inclisiran) on carotid plaque characteristics as assessed by ultrasound, thereby contributing valuable data to inform clinical practice.",[52,53,54],"Carotid Plaque","Hyperlipidemia","Echocardiography",[56,57,54,58],"inclisiran","carotid plaque","hyperlipidmia","NOT_YET_RECRUITING","2024-09-04",{"date":62,"type":63},"2024-09-19","ACTUAL",{"date":65,"type":46},"2024-09-20",{"date":67,"type":46},"2026-09-30",{"name":5,"class":6}]